Cobra Biologics Ltd. And University of Manchester Announce Collaboration To Improve Industrial Scale-Up Of Mammalian Cell Bioprocessing

Published: Sep 24, 2015

Agreement brings together academic and industrial expertise for the scaled manufacture of therapeutic proteins

Keele and Manchester, UK, 24 September 2015: Cobra Biologics (Cobra), international CDMO of biologics and pharmaceuticals, and Alan Dickson, Professor of Biotechnology at The University of Manchester (UoM) today announced a two year collaboration focused on improving understanding of cellular bioprocessing required for the scaled production of therapeutic proteins. The collaboration is supported via the FLexible Interchange Programme (FLIP) Scheme from the Biotechnology and Biological Sciences Research Council (BBSRC).

The partnership will address the need for greater predictability and certainty in process development and scale-up for the production of protein-based biopharmaceuticals for application in therapeutic areas including cancer and inflammation. The agreement will enable the exchange of knowledge, technology and skills and will allow Cobra access to UoM’s internationally renowned academic and associated research group. Professor Dickson will benefit from Cobra’s production data and significant operational knowledge of industrial manufacturing processes.

Financial terms and terms relating to IP have not been disclosed.

Dr Daniel Smith, CSO Cobra Biologics, said: “This is an exciting and unique opportunity for Cobra Biologics to gain scientific and technological insights from one of the senior UK academics working in the bioprocessing area.

“In addition, Professor Dickson has links and collaborations with UK and international academics, addressing all aspects of production of biopharmaceuticals.

“The insights of Professor Dickson into the various processes and tools used, combined with historical data case studies undertaken by Cobra Biologics, will allow better definition and enhancement of our current manufacturing processes and to build towards the idealised platforms and processes for future manufacture of innovator and biosimilar molecules.” Professor Alan Dickson, The University of Manchester, commented: “For an academic, FLIP support offers a tremendous opportunity to place the intellectual driver of research in the context of commercial perspectives.

“In working with colleagues at Cobra Biologics over the next two years, we hope to develop predictive visions for choice, manipulation and decision-making in manufacturing processes. The collaboration will offer long-term benefits for the University of Manchester, Cobra Biologics and, consequently, for the biopharmaceuticals sector in the North West of England.

“This is a true exchange of vision across the industrial/academic interface, in which both partners will learn from each other's perspectives, with learnings that will be translated to subsequent research projects and commercial activities.”

ENDS

Notes to Editors:

Dr Daniel Smith and Professor Alan Dickson are available for comment.
Contacts
Media enquiries
Sarah Jeffery
Zyme Communications
E-mail: sarah.jeffery@zymecommunications.com
Phone: +44 (0) 7771 730919
At Cobra Biologics
Peter Colman
Chief Executive Officer
E-mail: peter.coleman@cobrabio.com
Phone: +44 (0)1782 714181

About Cobra Biologics (www.cobrabio.com)

Cobra Biologics is a leading international contract manufacturing organisation (CMO) of biologics and pharmaceuticals for clinical and commercial supply. Cobra has three GMP approved facilities, each with expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract services, stretching from cell line and process development through to fill and finish for the supply of products for clinical trials and the commercial market.

We take pride in manufacturing excellence and being a trusted provider, delivering what we promise and helping our customers to develop medicines for the benefit of patients. Cobra supplies manufacturing solutions to the pharmaceutical industry covering antibodies, recombinant proteins, viruses, phage, DNA, whole cell vaccines and therapeutics as well as biologics and small molecule API lyophilisation and fill finish.

About The University of Manchester (www.manchester.ac.uk)

The University of Manchester, a member of the prestigious Russell Group of British universities, is the largest and most popular university in the UK. It has 20 academic schools and hundreds of specialist research groups undertaking pioneering multi-disciplinary teaching and research of worldwide significance.

The University of Manchester is one of the country’s major research institutions, rated fifth in the UK in terms of ‘research power’ (REF 2014), and has had no fewer than 25 Nobel laureates either work or study there. The University had an annual income of £886 million in 2013/14.

About the BBSRC (www.bbsrc.ac.uk)

The Biotechnology and Biological Sciences Research Council (BBSRC) invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond. Funded by Government, and with an annual budget of around £484M (2013-2014), we support research and training in universities and strategically funded institutes. BBSRC research, and the people we fund, is helping society to meet major challenges, such as food security, green energy and industries, and living healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.

Help employers find you! Check out all the jobs and post your resume.

Back to news